Navigation Links
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Date:7/19/2009

care, versus placebo plus standard of care, in serologically active (i.e., autoantibody-positive) patients with SLE. This is the largest clinical trial program ever conducted in lupus patients. BLISS-52 randomized and treated 865 patients at 90 clinical sites in 13 countries, primarily in Asia, South America and Eastern Europe. BLISS-76 enrolled and randomized 826 patients at 133 clinical sites in 19 countries, primarily in North America and Europe. The design of the two trials is similar, but the duration of therapy in the two studies is different - 52 weeks for BLISS-52 and 76 weeks for BLISS-76. The data from BLISS-76 will be analyzed after 52 weeks in support of a potential Biologics License Application in the United States and Marketing Authorization Application in Europe and other regions. HGS designed the Phase 3 program for belimumab in collaboration with GSK and leading international SLE experts, and the program is being conducted under a Special Protocol Assessment agreement with FDA.

The primary efficacy endpoint of BLISS-52 and BLISS-76 is the patient response rate at Week 52, as defined by: (1) a reduction from baseline of at least 4 points on the SELENA SLEDAI disease activity scale (which indicates a clinically important reduction in SLE disease activity); (2) no worsening of disease as measured by the Physician's Global Assessment (worsening defined as an increase of 0.30 points or more from baseline); and (3) no new BILAG A organ domain score (which indicates a severe flare of lupus disease activity) and no more than one new BILAG B organ domain score (which would indicate a moderate flare of disease activity). Analysis for the primary endpoint is based on intention-to-treat (ITT) and adjusted for baseline stratification factors, including SELENA SLEDAI score, proteinuria and race.

In each of the two Phase 3 trials, patients were randomized to one of three treatment groups: 10 mg/kg belimumab (BLISS-52
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at June 30, ... March 31, 2014."The second half of 2014 will be an ... milestones for a number of our late-stage clinical programs," said ... "The first of these is the potential US and EU ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
(Date:7/31/2014)... Mass. , July 31, 2014  Decision Resources ... technology market intelligence product Marketrack to now include ChinaTrack; ... device landscape in an interactive dashboard providing detailed ... procedure volumes at a hospital level. Other ... , Updated data feed: In addition to end-user surveys ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... SAN DIEGO, Jan. 11 CareFusion (NYSE: CFN ... the Food and Drug Administration (FDA) has given the company ... SE line of infusion pumps (also known as the Signature ... Medical Products division of Cardinal Health, has been operating under ...
... , PRINCETON, N.J., Jan. 11 Covance ... present at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, ... a live webcast of the presentation at www.covance.com . ... on 10 minutes early. , Covance, with headquarters in Princeton, New ...
Cached Medicine Technology:FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump 2
(Date:7/31/2014)... Vegas, NV (PRWEB) July 31, 2014 Hook Your ... way to get ex’s to feel emotionally hungry for their partner, ... a second chance. This little trick has been taught to ... , After a quick Hook Your Ex review , Shane ... who is suffering pain from a breakup a second chance at ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary is ... Anthony Le Donne and Peter J. Bellini. Both began ... to United is a Director of Non-Degree Programs, Mark ... , Anthony Le Donne, Assistant Professor of New Testament, ... teaches New Testament, Second Temple Judaism, and Greek courses. ...
(Date:7/31/2014)... July 31, 2014 Cosmetic Town is ... Plastic Surgeons to consumers considering cosmetic treatments. The ... peers whose goal is to educate prospective patients on ... selected through a validated referral system that helps patients ... best in their respective fields. , Cosmetic Town ...
(Date:7/31/2014)... 31, 2014 The VitaSleep FDA cleared ... airway and provide an easier breathing capacity by slightly ... are that people can breathe easier and helps reduce ... adjustable so that it can meet the needs of ... is often shared by actual customer reviews. Johathan ...
(Date:7/31/2014)... Ce-Classes.com has developed a Learning ... agencies to pass inspections and audits. Ce-Classes.com ... their accreditation and state licensing criteria by providing ... Healthcare administrators can monitor employee compliance with mandatory ... Courses can be developed based on the policies ...
Breaking Medicine News(10 mins):Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Growing Seminary Welcomes New Faculty 2Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3
... and his colleagues from the Duke University of Medical Center ... Obese people had lower rate of medical testing and ... received mammography tests, Pap smear tests and flu vaccination. The ... evidence correlated with the results for black people. ...
... prone to losing their eyesight later in life than non-smokers, ... in the UK with age-related macular degeneration (AMD). Of ... result of smoking.// ,AMD usually develops after a ... the retina of the eye. A report by AMD Alliance ...
... has been reported that bacteria lurking in household ... endotoxins that may trigger asthma and asthma-related symptoms ... has been established between endotoxin levels and the ... use, and wheezing. These relationships were strongest for ...
... to its credit. Magnetic Resonance Spectrometry (MRS) as is ... brain infections such as brain abscess, and an accurate// ... will also help distinguish between brain tumor and other ... way. ,Several hundred serious brain infections such as ...
... if mothers feel that their neighborhoods are safe then ... the study also points out that this does not ... less overweight in comparison with their counterparts in unsafe ... 20 U.S. cities, researchers reported these findings in the ...
... report published by the Department of Veterans Affairs (VA) ... levels and provided a guideline to do so.// ... heart and blood vessels, but they may also increase ... Alzheimer’s disease. ,During September, celebrating the National Cholesterol ...
Cached Medicine News:Health News:Is your house safe enough to protect against asthma attacks? 2Health News:Safe Neighborhood Means Less TV For Preschool Children 2Health News:High Cholesterol Can Be Controlled By Screening And Prevention 2
Liberty Single Piece PMMA Lens with UV Absorber....
... sterile nonpyrogenic, transparent viscoelastic solution of highly ... mg/ml of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25 C and ...
... with optimum molecular weight and viscosity, so ... coats and protects the delicate structures of ... balance of cohesion, adhesion, and pseudoplasticity to ... phaco surgeon expects from an ophthalmic viscoelastic ...
... (1.8%) viscoelastic solution combines maximum intraocular protection ... a deep anterior chamber and protects the ... for routine cataract surgery but can be ... viscoelastic. Combine all these properties with the ...
Medicine Products: